FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4207044707> ?p ?o ?g. }

• W4207044707 endingPage "i433" @default.
• W4207044707 startingPage "i433" @default.
• W4207044707 abstract "Abstract Background The clinical course of ulcerative colitis (UC) is characterized by periods of exacerbation and remission. 5-aminosalicylic acid (5-ASA) remains the treatment of choice in patients with mild-to-moderate UC, due to its beneficial effect in preventing relapse. Treatment options (immunomodulators [IMM] and biological agents) have increased, so it is important recognizing patients at risk of medical therapy failure that can appropriately optimize treatment escalation for better control of the disease. Little is known about the long-term course of the disease among patients in remission with 5-ASA. Aims To assess long-term efficacy of 5-ASA (no IMM, biological therapy or colectomy) and to identify predictive factors of non-response. Methods An observational, retrospective, single-centre, case-control study was performed. All consecutive patients with UC followed in our Hospital from January 2000 until June 2020 initially treated with 5-ASA (±steroids) with a minimum follow-up of 1 year were screened for eligibility. Exclusion criteria were 5-ASA toxicity/intolerance or initial treatment with IMM/biologic agents.Time until step-up was recorded. Demographic, clinical, endoscopic, biochemical, and histological variables at the diagnosis were recorded and a Cox regression was performed to identify predictive factors for step-up strategy. Results 218 patients (mean age 41,4±14,6 years; 54,5% female; mean follow-up10,1±1,9 years) were analysed, 28% needed treatment with biologics or IMM, mainly due to steroid-dependence. Among “5-ASA responders”, 72% and 48% had sustained endoscopic and histological remission, respectively. The probability of step-up at 1 year, 5 years and 10 years was 10, 18 and 25%, respectively. “Step-up patients” had higher rates of hospitalization, disease extent progression, extraintestinal manifestations and colonic stenosis and/or pseudo-polyps (p&lt;0,05). Montreal E3 (HR:2,31;95% CI: 1,12-4,68), steroids at first flare (HR:3,45;95% CI: 1,26-7,29), lower 5-ASA maintenance dose (HR: 1,97;95%;CI:1,12-3,29), lower haemoglobin level (HR:1,45;95% CI: 1,11-3,24) and DUBLIN Score≥4 (HR:1,81;95% CI: 1,269-4,59) were factors associated with the step-up strategy, in multivariate analysis. Conclusion 5-ASA is an effective maintenance therapy; a satisfactory response was achieved in 72% of the patients after a mean time of follow-up of 10 years. Extensive colitis, higher DUBLIN Score, lower doses of 5-ASA, need for steroid and anaemia can predict a worse prognosis at the initial diagnosis and are associated with higher therapeutic requirements. These findings may be used in our clinical practice to identify patients that might benefit from an early step-up approach and minimize the morbidity associated with uncontrolled disease." @default.
• W4207044707 created "2022-01-26" @default.
• W4207044707 creator A5002822425 @default.
• W4207044707 creator A5015523469 @default.
• W4207044707 creator A5027177021 @default.
• W4207044707 creator A5065004542 @default.
• W4207044707 creator A5071873090 @default.
• W4207044707 creator A5074292397 @default.
• W4207044707 creator A5076445998 @default.
• W4207044707 date "2022-01-01" @default.
• W4207044707 modified "2023-10-18" @default.
• W4207044707 title "P455 Aminosalicylates in Ulcerative Colitis: old but gold?" @default.
• W4207044707 doi "https://doi.org/10.1093/ecco-jcc/jjab232.582" @default.
• W4207044707 hasPublicationYear "2022" @default.
• W4207044707 type Work @default.
• W4207044707 citedByCount "0" @default.
• W4207044707 crossrefType "journal-article" @default.
• W4207044707 hasAuthorship W4207044707A5002822425 @default.
• W4207044707 hasAuthorship W4207044707A5015523469 @default.
• W4207044707 hasAuthorship W4207044707A5027177021 @default.
• W4207044707 hasAuthorship W4207044707A5065004542 @default.
• W4207044707 hasAuthorship W4207044707A5071873090 @default.
• W4207044707 hasAuthorship W4207044707A5074292397 @default.
• W4207044707 hasAuthorship W4207044707A5076445998 @default.
• W4207044707 hasBestOaLocation W42070447071 @default.
• W4207044707 hasConcept C126322002 @default.
• W4207044707 hasConcept C141071460 @default.
• W4207044707 hasConcept C167135981 @default.
• W4207044707 hasConcept C23131810 @default.
• W4207044707 hasConcept C2776667177 @default.
• W4207044707 hasConcept C2777014857 @default.
• W4207044707 hasConcept C2779134260 @default.
• W4207044707 hasConcept C2780479503 @default.
• W4207044707 hasConcept C71924100 @default.
• W4207044707 hasConcept C90924648 @default.
• W4207044707 hasConceptScore W4207044707C126322002 @default.
• W4207044707 hasConceptScore W4207044707C141071460 @default.
• W4207044707 hasConceptScore W4207044707C167135981 @default.
• W4207044707 hasConceptScore W4207044707C23131810 @default.
• W4207044707 hasConceptScore W4207044707C2776667177 @default.
• W4207044707 hasConceptScore W4207044707C2777014857 @default.
• W4207044707 hasConceptScore W4207044707C2779134260 @default.
• W4207044707 hasConceptScore W4207044707C2780479503 @default.
• W4207044707 hasConceptScore W4207044707C71924100 @default.
• W4207044707 hasConceptScore W4207044707C90924648 @default.
• W4207044707 hasIssue "Supplement_1" @default.
• W4207044707 hasLocation W42070447071 @default.
• W4207044707 hasOpenAccess W4207044707 @default.
• W4207044707 hasPrimaryLocation W42070447071 @default.
• W4207044707 hasRelatedWork W2026116136 @default.
• W4207044707 hasRelatedWork W2056666990 @default.
• W4207044707 hasRelatedWork W2062132000 @default.
• W4207044707 hasRelatedWork W2336265015 @default.
• W4207044707 hasRelatedWork W2409037155 @default.
• W4207044707 hasRelatedWork W2410674763 @default.
• W4207044707 hasRelatedWork W2414966063 @default.
• W4207044707 hasRelatedWork W4210249856 @default.
• W4207044707 hasRelatedWork W1655786854 @default.
• W4207044707 hasRelatedWork W2337243043 @default.
• W4207044707 hasVolume "16" @default.
• W4207044707 isParatext "false" @default.
• W4207044707 isRetracted "false" @default.
• W4207044707 workType "article" @default.